Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | PLK4 | O00444 | 1/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16060851 | 0.81 | PDE3B (0.45) | MAPTKDM4EGAATDP1CLK4 | |
| SCHEMBL4872103 | 0.81 | GAA (0.60) | MAPTKDM4EGAATDP1HTT | |
| SCHEMBL4522255 | 0.78 | GSTP1 (0.60) | MAPTKDM4EGAATDP1NOTUM | |
| SCHEMBL1013408 | 0.77 | KIF11 (0.44) | PARP1NOTUMBACE1 | |
| SCHEMBL3372323 | 0.74 | MAPT (1.00) | MAPTKDM4EGAATDP1HPGD | |
| SCHEMBL6798828 | 0.73 | MAPT (0.69) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL3263382 | 0.73 | ALDH1A1 (0.53) | MAPTKDM4EGAATDP1PLK4 | |
| SCHEMBL11846035 | 0.71 | MAPT (0.91) | MAPTKDM4EGAATDP1HPGD | |
| SCHEMBL2442343 | 0.69 | GSTP1 (0.62) | MAPTKDM4EHPGDMAPK1HTT | |
| SCHEMBL1754735 | 0.68 | POLB (0.57) | MAPTGAALIMK1CLK4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051925-A1 | METHODS FOR PREPARING PYRIDAZINONE DERIVATIVES | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2024-02-15 | — | — | US | disclosed |
| EP-4232436-A1 | PROCESS FOR THE PREPARATION OF 6-(4-NITRO-PHENOXY)-2H-PYRIDAZIN-3-ONE AND 6-(4-AMINO-PHENOXY)-2H-PYRIDAZIN-3-ONE DERIVATIVES AS INTERMEDIATES OF THYROID HORMONE ANALOGUES | Madrigal Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-116406356-A | Process for the preparation of 6- (4-nitro-phenoxy) -2H-pyridazin-3-one and 6- (4-amino-phenoxy) -2H-pyridazin-3-one derivatives as intermediates for thyroid hormone analogues | 马德里加尔制药公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-111909137-B | Pyridazinone derivative and application thereof | 深圳微芯生物科技股份有限公司 | 2023-05-30 | — | — | CN | disclosed |
| WO-2022087141-A1 | PROCESS FOR THE PREPARATION OF 6-(4-NITRO-PHENOXY)-2H-PYRIDAZIN-3-ONE AND 6-(4-AMINO-PHENOXY)-2H-PYRIDAZIN-3-ONE DERIVATIVES AS INTERMEDIATES OF THYROID HORMONE ANALOGUES | MADRIGAL PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022087141-A1 | PROCESS FOR THE PREPARATION OF 6-(4-NITRO-PHENOXY)-2H-PYRIDAZIN-3-ONE AND 6-(4-AMINO-PHENOXY)-2H-PYRIDAZIN-3-ONE DERIVATIVES AS INTERMEDIATES OF THYROID HORMONE ANALOGUES | MADRIGAL PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2020228577-A1 | PYRIDAZINONE DERIVATIVE AND USE THEREOF | 深圳微芯生物科技股份有限公司 | 2020-11-19 | — | — | WO | disclosed |
| CN-111909137-A | Pyridazinone derivative and application thereof | 深圳微芯生物科技股份有限公司 | 2020-11-10 | — | — | CN | disclosed |
| US-9663493-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9527819-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY | 2016-12-27 | — | — | US | disclosed |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | UNIVERSITE DE STRASBOURG (FR) | 2008-12-25 | — | — | US | disclosed |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | UNIVERSITE DE STRASBOURG (FR) | 2008-12-25 | — | — | US | disclosed |
| US-7300932-B2 | Pyrrolo[1,2-b]pyridazine derivatives | JAPAN TOBACCO INC. (JP) | 2007-11-27 | — | — | US | disclosed |
| US-20060142178-A1 | Method of treating cancer | BARNETT STANLEY F | 2006-06-29 | — | — | US | disclosed |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
| US-6960584-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050070545-A1 | For treatment or prevention of metabolic and cell proliferative diseases; modifying lipid metabolism | TULARIK INC. (US) | 2005-03-31 | — | — | US | disclosed |
| US-20040116432-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME LTD. (GB) | 2004-06-17 | — | — | US | disclosed |
| US-20040106540-A1 | Method of treating cancer | BARNETT STANLEY F (US) | 2004-06-03 | — | — | US | disclosed |
| US-20040102360-A1 | Combination therapy | BARNETT STANLEY F (US) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070545-A1 | For treatment or prevention of metabolic and cell proliferative diseases; modifying lipid metabolism | PC, ACACB, ACAT1 | MAPT 2498/4885KDM4E 2907/4885GAA 278/4885 |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | APP, PSEN1, PSEN2 | MAPT 32/4885KDM4E 2808/4885GAA 3526/4885 |
| US-20240051925-A1 | METHODS FOR PREPARING PYRIDAZINONE DERIVATIVES | CYP7A1, LIPC, CYP11B2 | MAPT 3117/4885KDM4E 2280/4885GAA 880/4885 |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | MAPT 1/4885KDM4E 4000/4885GAA 2288/4885 |
| US-20040102360-A1 | Combination therapy | MTOR, AKT2, PLK1 | MAPT 3086/4885KDM4E 2180/4885GAA 1689/4885 |
| US-20060142178-A1 | Method of treating cancer | PACSIN2, CTTN, TNK2 | MAPT 3209/4885KDM4E 2137/4885GAA 1693/4885 |
| US-20040106540-A1 | Method of treating cancer | PACSIN2, CTTN, PLK1 | MAPT 3059/4885KDM4E 2374/4885GAA 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.